BPC-157

BPC-157 is a synthetic peptide corresponding to a fragment of a protein originally isolated from gastric juice. Interest in the sequence began in the 1990s in the laboratory of Predrag Sikiric at the University of Zagreb, whose group characterized it as unusually stable in gastric acid compared with many short peptides — a property that made it convenient to administer in rodent protocols without the degradation seen with less stable sequences. Essentially the entire published record on this compound comes from rodent and in vitro work; there is no substantial controlled human literature.

The largest cluster of published studies examined tissue injury models in rats. Reports from the Zagreb group and collaborators described accelerated closure in experimentally transected Achilles tendon, medial collateral ligament, and muscle-crush models, and reduced lesion area in ethanol- and NSAID-induced gastric injury models. In several of those papers the authors measured biomechanical endpoints such as load-to-failure in the healing tendon, and histological endpoints such as fibroblast density and collagen organization, rather than surrogate markers alone. A commonly cited example is Krivic et al. (2006), which reported improved functional and biomechanical recovery in a rat Achilles transection model.

A second line of investigation concerned vascular and angiogenic mechanisms. Chang et al. (2011) reported increased expression of VEGF receptor 2 and downstream signalling in cultured tendon fibroblasts exposed to the peptide, and several rodent papers described the appearance of collateral vessels around an occluded segment in ischemia models. Related work has been interpreted through nitric oxide pathway involvement, based on experiments in which L-NAME and L-arginine co-treatment modified the observed rodent outcomes. These are mechanistic hypotheses generated in animal and cell systems, not established pathways.

A third area concerns the gastrointestinal tract and its neural connections, where studies described changes in mucosal integrity and in dopamine- and serotonin-system readouts in rats. This work is exploratory and has been discussed in the literature as preliminary.

The principal limitation of the BPC-157 record is its concentration in a small number of laboratories. Independent replication outside the originating group is limited, several papers report large effect sizes in small-n animal cohorts, and reporting of blinding and randomization varies. Pharmacokinetic characterization is sparse, and stability data across formulations and solvents are not well standardized in the published literature. A 2022 review by Seiwerth and colleagues summarized the preclinical body of work while also noting the absence of completed controlled clinical trials. Investigators designing new experiments should treat published rodent findings as hypothesis-generating and include appropriate vehicle controls, blinded outcome assessment, and independent analytical confirmation of the material used.